Science Corporation implants vision chip in first Stargardt patient
2 sources · TechCrunch AI · TechCrunch- Boom: Science Corporation implanted PRIMA chip in its first Stargardt disease patient
- Neutral: Max Hodak, ex-Neuralink co-founder, leads Science Corporation and presented at TechCrunch Disrupt
- Boom: PRIMA implant work is positioned as a step toward a novel brain-computer interface
The story in full
Science Corporation implanted its PRIMA vision-restoring chip in its first patient with Stargardt disease, according to a presentation at TechCrunch Disrupt on October 13, 2026. Max Hodak, former president and co-founder of Neuralink and now leading Science Corporation, described the procedure on stage at the event.
Hodak framed the PRIMA implant work as part of the company's broader path toward developing a novel brain-computer interface. Stargardt disease is an inherited retinal disorder that causes progressive central vision loss, typically beginning in childhood or adolescence.
Analysis
326 wordsOn October 13, 2026, Science Corporation announced at TechCrunch Disrupt that it had implanted its PRIMA vision-restoring chip in its first patient diagnosed with Stargardt disease. Max Hodak, who previously co-founded Neuralink and served as its president before departing to lead Science Corporation, made the announcement on stage. Stargardt disease is an inherited retinal disorder that causes progressive central vision loss, generally beginning in childhood or adolescence, and currently has no approved cure.
The significance of the announcement extends beyond a single surgical milestone. Hodak framed the PRIMA implant program not just as a standalone medical device effort but as a stepping stone toward developing a novel brain-computer interface. That framing matters because it positions Science Corporation as a competitor in the broader BCI space, which already includes Neuralink and several other well-funded ventures. Whether a retinal implant translates meaningfully into BCI capability is a genuine scientific and strategic question, and the company's choice to highlight that connection at a technology conference rather than a medical one signals how it wants to be perceived by investors and the industry.
None of the three camps, Pro-AI, Anti-AI, or Middle Ground, have published reactions to this story yet. Pro-AI voices would typically celebrate the implant as evidence that AI-adjacent hardware is delivering real medical benefits to patients with conditions that have had no treatment options. Anti-AI commentators would likely raise questions about informed consent, the pace of human trials, and whether commercial incentives are being prioritized over long-term safety data. Middle Ground observers would probably call for rigorous peer-reviewed follow-up before drawing conclusions about efficacy or the broader BCI roadmap Hodak outlined.
The most concrete thing to watch is whether Science Corporation publishes clinical outcome data for this first Stargardt patient, including any measurable improvement in central vision, and whether it files for regulatory review of PRIMA with the FDA or equivalent bodies. Those steps would move the story from a conference announcement toward a verifiable medical record.
Where do you stand?
Add your take
0 reader votesSign in with Google to pick a side and post. Your vote moves the story's Doom / Boom score.
